ACURライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (19 4月 2024 @ 23:26):

Stats
本日の出来高	40.00
平均出来高	1 036.00
時価総額	660 018
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.500
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Ross George K	Buy	50 000	Common Stock
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Skelly William G	Buy	50 000	Common Stock
2024-01-02	Skelly William G	Sell	50 000	Restricted Stock Units (2021 Plan)

INSIDER POWER
8.01
Last 100 transactions
Buy: 88 557 065 \| Sell: 8 647 538

ACURA PHARMACEUTICALS INC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ACURA PHARMACEUTICALS INC 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2020
収益:	$3.57M
総利益:	$0.00 (0.00 %)
EPS:	$-0.0400

FY	2019
収益:	$2.66M
総利益:	$0.00 (0.00 %)
EPS:	$-0.140

Financial Reports:

No articles found.

ACURA PHARMACEUTICALS INC

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.